Evaxion Biotech A/S는 암 및 감염성 질환에 대한 면역요법의 발견과 개발을 전문으로 하고 있습니다. 이 회사는 인간 면역 시스템을 해독하여 암과 감염성 질환을 치료할 면역요법을 개발하고 있습니다. 인공지능 기반 면역학 핵심 기술을 바탕으로 Evaxion은 다수의 파이프라인 제품 후보를 개발 중입니다. 또한 Evaxion은 세균성 및 바이러스성 감염을 예방하기 위한 백신 포트폴리오도 개발하고 있습니다.
How did EVAX's recent EPS compare to expectations?
The most recent EPS for Evaxion A/S is $-0.5, 뛰어넘다 expectations of $-0.3.
How did Evaxion A/S EVAX's revenue perform in the last quarter?
Evaxion A/S revenue for the last quarter is $-0.5
What is the revenue estimate for Evaxion A/S?
According to 4 of Wall street analyst, the revenue estimate of Evaxion A/S range from $0.0 to $0.0
What's the earning quality score for Evaxion A/S?
Evaxion A/S has a earning quality score of B/43.09247. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Evaxion A/S report earnings?
Evaxion A/S next earnings report is expected in 2026-08-05
What are Evaxion A/S's expected earnings?
Evaxion A/S expected earnings is $0.0, according to wall-street analysts.
Did Evaxion A/S beat earnings expectations?
Evaxion A/S recent earnings of $0.0 미달하다 expectations.